8-Year Survival with a Metastatic Thymic Neuroendocrine Tumor: Emphasis on Redefining “Treatment Objectives” Using “Personalized” Peptide Receptor Radionuclide Therapy with 177LU- and 90Y-Labeled Somatostatin Analogs

8-Year Survival with a Metastatic Thymic Neuroendocrine Tumor: Emphasis on Redefining “Treatment Objectives” Using “Personalized” Peptide Receptor Radionuclide Therapy with 177LU- and 90Y-Labeled Somatostatin Analogs

ABSTRACT: Objective: Peptide receptor radionuclide therapy (PRRT) with 90Yttrium (90Y)- and 177Lutetium (177Lu)-labeled somatostatin analogs are the accepted standard of care for treatment of metastatic well-differentiated neuroendocrine tumors (NET) of the midgut. More aggressive NETs (e.g., of med...

Full description

Bibliographic Details
Main Authors: Ameya D. Puranik, MD, FEBNM, Harshad R. Kulkarni, MD, Aviral Singh, MD, Richard P. Baum, MD, PhD
Format: Article
Language:English
Published: Elsevier 2015-01-01
Series:AACE Clinical Case Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2376060520302315

Internet

http://www.sciencedirect.com/science/article/pii/S2376060520302315

Similar Items